DGIdb - COPANLISIB Drug Record

COPANLISIB chembl:CHEMBL3218576 ApprovedAntineoplastic

Alternate Names:

BAY80-6946
BAY 80-6946
COPANLISIB
BAY-80-6946
chembl:CHEMBL3218576
chemidplus:1032568-63-0
pubchem.compound:24989044
drugbank:12483

Drug Info:

Notes	pan-PI3K inhibitor
Drug Class	Kinase Inhibitors
Pharmaceutical Developer	Bayer
Source Reported Drug Name(s)	BAY80-6946
Drug Class	PI3K Inhibitor
Drug Type	small molecule
Drug Groups	approved
Drug Groups	investigational
Drug Categories	antineoplastic agents
Drug Categories	antineoplastic and immunomodulating agents
Drug Categories	bcrp/abcg2 substrates
Drug Categories	cytochrome p-450 cyp3a substrates
Drug Categories	cytochrome p-450 cyp3a4 substrates
Drug Categories	cytochrome p-450 cyp3a4 substrates with a narrow therapeutic index
Drug Categories	cytochrome p-450 cyp3a5 substrates
Drug Categories	cytochrome p-450 cyp3a7 substrates
Drug Categories	cytochrome p-450 substrates
Drug Categories	heterocyclic compounds, fused-ring
Drug Categories	kinase inhibitor
Drug Categories	mate 2 inhibitors
Drug Categories	mate inhibitors
Drug Categories	p-glycoprotein substrates
Drug Categories	p-glycoprotein substrates with narrow therapeutic index

(7 More Sources)

Publications:

Patnaik et al., 2016, First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas., Ann. Oncol.
Liu et al., 2013, BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models., Mol. Cancer Ther.

COPANLISIB PIK3R4

Interaction Score: 0.39

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenomeClinicalTrial MyCancerGenome
COPANLISIB PIK3R6

Interaction Score: 0.39

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenomeClinicalTrial MyCancerGenome
COPANLISIB PIK3R1

Interaction Score: 0.35

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction PI3-kinase class I inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers MyCancerGenomeClinicalTrial MyCancerGenome ChemblInteractions
COPANLISIB PIK3R5

Interaction Score: 0.3

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction PI3-kinase class I inhibitor

PMIDs:
None found

Sources:
MyCancerGenomeClinicalTrial MyCancerGenome ChemblInteractions
COPANLISIB PIK3R3

Interaction Score: 0.29

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction PI3-kinase class I inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
MyCancerGenomeClinicalTrial MyCancerGenome ChemblInteractions
COPANLISIB PIK3R2

Interaction Score: 0.26

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction PI3-kinase class I inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
MyCancerGenomeClinicalTrial MyCancerGenome ChemblInteractions
COPANLISIB PIK3CD

Interaction Score: 0.24

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
None found

Sources:
MyCancerGenomeClinicalTrial DrugBank MyCancerGenome GuideToPharmacology ChemblInteractions
COPANLISIB PIK3CA

Interaction Score: 0.23

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction PI3-kinase class I inhibitor

Direct Interaction? False

PMIDs:
27672108 24170767

Sources:
ClearityFoundationBiomarkers CancerCommons MyCancerGenomeClinicalTrial OncoKB JAX-CKB DrugBank MyCancerGenome GuideToPharmacology ChemblInteractions
COPANLISIB PIK3C2A

Interaction Score: 0.21

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenome
COPANLISIB PIK3C2B

Interaction Score: 0.2

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenome
COPANLISIB PIK3CB

Interaction Score: 0.19

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
MyCancerGenomeClinicalTrial MyCancerGenome GuideToPharmacology ChemblInteractions
COPANLISIB PIK3C3

Interaction Score: 0.19

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenome
COPANLISIB PIK3C2G

Interaction Score: 0.19

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenome
COPANLISIB PIK3CG

Interaction Score: 0.11

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
MyCancerGenomeClinicalTrial MyCancerGenome GuideToPharmacology ChemblInteractions
COPANLISIB PTEN

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type endometrial carcinoma

Response Type sensitive

Approval Status Phase I

PMIDs:
27672108

Sources:
ClearityFoundationBiomarkers JAX-CKB
COPANLISIB KRAS

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Copanlisib + Refametinib

Indication/Tumor Type biliary tract cancer

Response Type sensitive

PMIDs:
24170767

Sources:
JAX-CKB
COPANLISIB ERBB2

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type Her2-receptor positive breast cancer

Response Type sensitive

Approval Status Preclinical - Cell line xenograft

PMIDs:
24170767

Sources:
JAX-CKB
COPANLISIB MTOR

Interaction Score: 0.02

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
GuideToPharmacology

CancerCommons: BAY80-6946
- Version: 25-July-2013
Alternate Names:

66563707 PubChem Drug ID

Drug Info:

Drug Class PI3K Inhibitor

Source Reported Drug Name(s) BAY80-6946

Pharmaceutical Developer Bayer

Publications:
DrugBank: DB12483
- Version: 5.1.7
Alternate Names:

COPANLISIB DrugBank Drug Name

1032568-63-0 CAS Number

Aliqopa Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Groups investigational

Publications:
MyCancerGenome: BAY80-6946
- Version: 20-Jun-2017
Alternate Names:

Drug Info:

Drug Class Kinase Inhibitors

Notes pan-PI3K inhibitor

Publications:

JAX-CKB: Copanlisib

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Patnaik et al., 2016, First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas., Ann. Oncol.

Liu et al., 2013, BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models., Mol. Cancer Ther.

GuideToPharmacology: 223366204
- Version: 29-September-2020
Alternate Names:

COPANLISIB GuideToPharmacology Ligand Name

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL3218576
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ClearityFoundationBiomarkers: BAY80-6946
- Version: 26-July-2013
Alternate Names:

Drug Info:

Publications:
MyCancerGenomeClinicalTrial: BAY80-6946
- Version: 30-February-2014
Alternate Names:

Drug Info:

Publications:
OncoKB: Copanlisib
- Version: 23-July-2020
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL3218576
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
TALC: BAY80-6946
- Version: 12-May-2016
Alternate Names:

Drug Info:

Publications:

Mechanism of Interaction	PI3-kinase class I inhibitor
Direct Interaction	yes

Direct Interaction?	False
Endogenous Drug?	False
Specific Action of the Ligand	Inhibition

Indication/Tumor Type	endometrial carcinoma
Response Type	sensitive
Approval Status	Phase I

combination therapy	Copanlisib + Refametinib
Indication/Tumor Type	biliary tract cancer
Response Type	sensitive

Indication/Tumor Type	Her2-receptor positive breast cancer
Response Type	sensitive
Approval Status	Preclinical - Cell line xenograft

COPANLISIB	DrugBank Drug Name
1032568-63-0	CAS Number
Aliqopa	Drug Brand

COPANLISIB Drug Record

COPANLISIB chembl:CHEMBL3218576 ApprovedAntineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: MyCancerGenomeClinicalTrial MyCancerGenome

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: MyCancerGenomeClinicalTrial MyCancerGenome

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction PI3-kinase class I inhibitor Direct Interaction yes

PMIDs: None found

Sources: ClearityFoundationBiomarkers MyCancerGenomeClinicalTrial MyCancerGenome ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction PI3-kinase class I inhibitor

PMIDs: None found

Sources: MyCancerGenomeClinicalTrial MyCancerGenome ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction PI3-kinase class I inhibitor Direct Interaction yes

PMIDs: None found

Sources: MyCancerGenomeClinicalTrial MyCancerGenome ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction PI3-kinase class I inhibitor Direct Interaction yes

PMIDs: None found

Sources: MyCancerGenomeClinicalTrial MyCancerGenome ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction? False Endogenous Drug? False Specific Action of the Ligand Inhibition

PMIDs: None found

Sources: MyCancerGenomeClinicalTrial DrugBank MyCancerGenome GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction PI3-kinase class I inhibitor Direct Interaction? False

PMIDs: 27672108 24170767

Sources: ClearityFoundationBiomarkers CancerCommons MyCancerGenomeClinicalTrial OncoKB JAX-CKB DrugBank MyCancerGenome GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: MyCancerGenome

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: MyCancerGenome

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Inhibition Endogenous Drug? False Direct Interaction? False

PMIDs: None found

Sources: MyCancerGenomeClinicalTrial MyCancerGenome GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: MyCancerGenome

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: MyCancerGenome

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Inhibition Endogenous Drug? False Direct Interaction? False

PMIDs: None found

Sources: MyCancerGenomeClinicalTrial MyCancerGenome GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type endometrial carcinoma Response Type sensitive Approval Status Phase I

PMIDs: 27672108

Sources: ClearityFoundationBiomarkers JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Copanlisib + Refametinib Indication/Tumor Type biliary tract cancer Response Type sensitive

PMIDs: 24170767

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type Her2-receptor positive breast cancer Response Type sensitive Approval Status Preclinical - Cell line xenograft

PMIDs: 24170767

Sources: JAX-CKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Inhibition Endogenous Drug? False Direct Interaction? False

PMIDs: None found

Sources: GuideToPharmacology

CancerCommons: BAY80-6946

Alternate Names: 66563707 PubChem Drug ID

Drug Info: Drug Class PI3K Inhibitor Source Reported Drug Name(s) BAY80-6946 Pharmaceutical Developer Bayer

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
MyCancerGenomeClinicalTrial MyCancerGenome

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
MyCancerGenomeClinicalTrial MyCancerGenome

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction PI3-kinase class I inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers MyCancerGenomeClinicalTrial MyCancerGenome ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction PI3-kinase class I inhibitor

PMIDs:
None found

Sources:
MyCancerGenomeClinicalTrial MyCancerGenome ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction PI3-kinase class I inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
MyCancerGenomeClinicalTrial MyCancerGenome ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction PI3-kinase class I inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
MyCancerGenomeClinicalTrial MyCancerGenome ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
None found

Sources:
MyCancerGenomeClinicalTrial DrugBank MyCancerGenome GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction PI3-kinase class I inhibitor

Direct Interaction? False

PMIDs:
27672108 24170767

Sources:
ClearityFoundationBiomarkers CancerCommons MyCancerGenomeClinicalTrial OncoKB JAX-CKB DrugBank MyCancerGenome GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
MyCancerGenome

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
MyCancerGenome

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
MyCancerGenomeClinicalTrial MyCancerGenome GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
MyCancerGenome

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
MyCancerGenome

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
MyCancerGenomeClinicalTrial MyCancerGenome GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type endometrial carcinoma

Response Type sensitive

Approval Status Phase I

PMIDs:
27672108

Sources:
ClearityFoundationBiomarkers JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Copanlisib + Refametinib

Indication/Tumor Type biliary tract cancer

Response Type sensitive

PMIDs:
24170767

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type Her2-receptor positive breast cancer

Response Type sensitive

Approval Status Preclinical - Cell line xenograft

PMIDs:
24170767

Sources:
JAX-CKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
GuideToPharmacology

Alternate Names:

66563707 PubChem Drug ID

Drug Info:

Drug Class PI3K Inhibitor

Source Reported Drug Name(s) BAY80-6946

Pharmaceutical Developer Bayer

Alternate Names:

COPANLISIB DrugBank Drug Name

1032568-63-0 CAS Number

Aliqopa Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Groups investigational

Drug Info:

Drug Class Kinase Inhibitors

Notes pan-PI3K inhibitor

Alternate Names:

COPANLISIB GuideToPharmacology Ligand Name